G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $20.01, for a total transaction of $4,002,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Medimmune Ventures, Inc. also recently made the following trade(s):
- On Friday, December 1st, Medimmune Ventures, Inc. sold 133,906 shares of G1 THERAPEUTICS stock. The shares were sold at an average price of $19.75, for a total transaction of $2,644,643.50.
Shares of G1 THERAPEUTICS (NASDAQ:GTHX) opened at $19.53 on Friday. G1 THERAPEUTICS has a twelve month low of $12.04 and a twelve month high of $28.67.
GTHX has been the topic of several analyst reports. Cowen restated a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, November 8th. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. G1 THERAPEUTICS has a consensus rating of “Buy” and a consensus target price of $29.75.
A number of institutional investors and hedge funds have recently bought and sold shares of GTHX. American International Group Inc. acquired a new stake in G1 THERAPEUTICS in the third quarter worth $130,000. California State Teachers Retirement System acquired a new stake in G1 THERAPEUTICS in the third quarter worth $319,000. Schwab Charles Investment Management Inc. acquired a new stake in G1 THERAPEUTICS in the third quarter worth $364,000. Alps Advisors Inc. acquired a new stake in G1 THERAPEUTICS in the second quarter worth $444,000. Finally, Bank of New York Mellon Corp acquired a new stake in G1 THERAPEUTICS in the third quarter worth $568,000. Institutional investors own 43.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Medimmune Ventures, Inc. Sells 200,000 Shares of G1 THERAPEUTICS (GTHX) Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/08/medimmune-ventures-inc-sells-200000-shares-of-g1-therapeutics-gthx-stock.html.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.